Status:
COMPLETED
Sitagliptin Treatment in Diabetic COVID-19 Positive Patients
Lead Sponsor:
University of Milan
Collaborating Sponsors:
Papa Giovanni XXIII Hospital
Fondazione IRCCS Policlinico San Matteo di Pavia
Conditions:
Covid19
Eligibility:
All Genders
18+ years
Brief Summary
Coronavirus Pathology is frequently associated with both diabetes mellitus and metabolic syndrome. In particular, results of observational studies and meta-analyzes configure diabetes as one of the ma...
Detailed Description
An observational, retrospective-case control, multi-center study is proposed to evaluate any effects of Sitagliptin on clinical, laboratory and instrumental parameters in the course of hospitalization...
Eligibility Criteria
Inclusion
- Diagnosis of type 2 diabetes, according to ADA 2020 criteria
- Diagnosis of COVID-19 (positive SARS-COV2 RNA buffer) with pneumonia, with or without an increase in inflammation indexes, with or without respiratory failure
Exclusion
- Pregnancy
- Type 1 diabetes
- Presence of other acute infections in place
- Presence of serious diseases or conditions that make the patient unsuitable for the study
Key Trial Info
Start Date :
May 14 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 15 2020
Estimated Enrollment :
338 Patients enrolled
Trial Details
Trial ID
NCT04382794
Start Date
May 14 2020
End Date
June 15 2020
Last Update
July 9 2020
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
ASST FBF-Sacco P.O. Sacco
Milan, MI, Italy, 20157
2
Papa Giovanni XXIII Hospital
Bergamo, Italy, 24127
3
Ospedale dell'Angelo, Venezia-Mestre
Mestre, Italy, 30174
4
Humanitas Hospital
Milan, Italy, 20089